Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-ACT long-term observational follow-up of aHSCT for refractory relapsing-remitting multiple sclerosis
NL-OMON53285Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous hematopoietic stem cells in multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Primary endpoint: No evidence of disease activity. Started Sep 2023; status: recruiting.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON53285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53285.